Ideal for

Individuals with low sexual desire

Premenopausal women with HSDD

Those seeking non-hormonal support

Patients using on-demand therapy under medical guidance

Libido

Bremelanotide (PT-141)

Bremelanotide (PT-141) is a prescription peptide therapy designed to support healthy sexual desire by targeting the brain’s natural melanocortin pathways. Unlike traditional treatments that primarily improve blood flow, Bremelanotide works centrally to help enhance libido and sexual arousal. It is FDA-approved for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women and is administered on an as-needed basis under the guidance of a healthcare provider. With its unique mechanism of action, Bremelanotide offers a non-hormonal approach to improving sexual wellness and intimacy for appropriate patients.

KEY BENEFITS

Helps support healthy sexual desire in appropriate individuals diagnosed with HSDD.
Works through central nervous system pathways rather than hormonal mechanisms.
May improve sexual interest and reduce distress associated with low sexual desire.
Administered on an as-needed basis instead of requiring daily dosing.
Provides a non-hormonal treatment option for eligible patients.

INGREDIENTS

Bremelanotide (PT-141) is a synthetic peptide and melanocortin receptor agonist that acts primarily on the central nervous system rather than directly on blood vessels or hormones. It activates melanocortin receptors involved in sexual desire pathways in the brain and is FDA-approved as a prescription medication for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike medications that work by increasing blood flow, Bremelanotide works by modulating neural pathways associated with sexual motivation and desire.

DIRECTIONS

Use only under the supervision of a qualified healthcare provider.
The FDA-approved formulation is administered as a 1.75 mg subcutaneous injection at least 45 minutes before anticipated sexual activity.
Do not use more than one dose within 24 hours and no more than eight doses per month.
If no meaningful improvement is observed after approximately 8 weeks of treatment, consult your healthcare provider regarding continued use.
Avoid use in individuals with uncontrolled hypertension or known cardiovascular disease unless specifically advised by a physician.

FAQ

Q: What is Bremelanotide (PT-141)?
A: Bremelanotide is a prescription peptide medication that activates melanocortin receptors in the brain to help improve sexual desire in eligible patients.

Q: What is it used for?
A: It is FDA-approved for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.

Q: How does PT-141 work?
A: It stimulates melanocortin receptors in the brain involved in sexual desire and arousal pathways rather than increasing blood flow directly.

Q: How quickly does it work?
A: The approved injection is generally administered about 45 minutes before anticipated sexual activity, although individual responses may vary.

Q: Can it be used every day?
A: No. The approved guidance recommends no more than one dose in 24 hours and no more than eight doses per month.

Q: Is it a hormone?
A: No. It is a synthetic peptide and a melanocortin receptor agonist, making it a non-hormonal therapy.

Q: Who should avoid using it?
A: People with uncontrolled high blood pressure or cardiovascular disease should avoid its use unless specifically directed by a healthcare professional.

REFERENCES

Food and Drug Administration. (2019). Vyleesi (bremelanotide injection) prescribing information. Retrieved from FDA.
Edinoff, A. N., et al. (2022). Bremelanotide for treatment of female hypoactive sexual desire disorder. Cureus, 14(1). Retrieved from PubMed.
Mayer, D., et al. (2020). New drug approved for treating hypoactive sexual desire disorder in premenopausal women. Journal of Midwifery & Women’s Health. Retrieved from PubMed.
Clayton, A. H., et al. (2016). Bremelanotide for female sexual dysfunctions in premenopausal women. Drugs in Context. Retrieved from PubMed.

A medical intake form is required prior to receiving a prescription. A licensed healthcare provider will review it and determine your eligibility for this product.

Want to Know More About Our Products?

Eternelle is a virtual medical clinic providing prescription treatments through secure telehealth consultations. We offer personalized, medically supervised care focused on hair growth, skin health, energy, and overall wellness. Our mission is to deliver safe, effective, and accessible prescription solutions tailored to your individual health goals.

LINKS

CONTACT US

Orange County, CA
(Virtual Services Nationwide)

949-990-4490

hello@eternellehealth.com

Treatments

Weight Loss

Tirzepatide & Semaglutide for appetite control and lasting fat loss.

Skin & Hair

Targeted prescriptions for clearer skin, radiance, and fuller hair growth.

Longevity & Vitality

NAD+ therapy to restore cellular energy, brain function, and healthy aging.

Healing & Performance

Speed recovery, improve movement, and peak performance.

Hormone & Sexual Health

Support healthy libido, mood, energy, and hormonal wellness.

Ideal for

Individuals with low sexual desire

Premenopausal women with HSDD

Those seeking non-hormonal support

Patients using on-demand therapy under medical guidance

Bremelanotide (PT-141)